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Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD),
lung fibrosis, and lung cancer, pose a huge socio-economic burden on society and
are one of the leading causes of death worldwide. In the past, culture-dependent
techniques could not detect bacteria in the lungs, therefore the lungs were considered
a sterile environment. However, the development of culture-independent techniques,
particularly 16S rRNA sequencing, allowed for the detection of commensal microbes
in the lung and with further investigation, their roles in disease have since emerged.
In healthy individuals, the predominant commensal microbes are of phylum Firmicutes
and Bacteroidetes, including those of the genera Veillonella and Prevotella. In contrast,
pathogenic microbes (Haemophilus, Streptococcus, Klebsiella, Pseudomonas) are often
associated with lung diseases. There is growing evidence that microbial metabolites,
structural components, and toxins from pathogenic and opportunistic bacteria have the
capacity to stimulate both innate and adaptive immune responses, and therefore can
contribute to the pathogenesis of lung diseases. Here we review themultiple mechanisms
that are altered by pathogenic microbiomes in asthma, COPD, lung cancer, and lung
fibrosis. Furthermore, we focus on the recent exciting advancements in therapies that
can be used to restore altered microbiomes in the lungs.
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INTRODUCTION
The lungs are vital organs that facilitate gas exchange during respiration. They are highly susceptible
to disease risk factors such as exposure to air pollution, occupational exposure to toxins, cigarette
smoke and infections. Hence, the burden of chronic lung diseases (CLDs) is rising (1–4). Lung
diseases are the second leading cause of death worldwide (after cardiovascular disease) and account
for more than 10% of disability-adjusted life years (5). Asthma, chronic obstructive pulmonary
disease (COPD), idiopathic pulmonary fibrosis (IPF), and lung cancer are the most prevalent
CLDs globally.
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Briefly, asthma and COPD are chronic inflammatory diseases
with different pathophysiology. The former is characterized
by repeated episodic symptoms like shortness of breath and
wheezing upon exposure to allergen, while the latter presents
with chronic inflammation and irreversible airflow limitation (6–
11). Around 334 million individuals suffer from asthma alone
and the global prevalence of the disease has increased by 12.6%
between 1990 and 2015 (12). Likewise, with a 44.2% increase
in incidence, COPD is now the third leading cause of death
worldwide (12, 13).
IPF is a progressive lung disease with a median survival rate
of 3–5 years after diagnosis (14–16). Recent studies show that the
rate of IPF is ∼3–9 per 100,000 for Europe and North America,
with limited data available on global prevalence (17, 18). It
is characterized by progressive fibrosis of the lungs with an
unknown cause leading to impaired forced expiratory volume,
vital capacity and mortality in patients with an advanced stage
of disease (19).
Lung cancer is one of the most commonly diagnosed cancers
worldwide. Lung cancer is categorized into two major subtypes;
85% are non-small cell lung cancers (NSCLCs) and 15% are small
cell lung cancers (20). Currently, lung cancer accounts for 18.4%
of total cancer related deaths and therefore imparts a huge socio-
economic burden on society (21). Furthermore, the prevalence
of lung cancer is expected to rise due to the continued increase in
risk factors such as smoking.
The causes of asthma, COPD, IPF and lung cancer are
multifactorial and influenced by both genetics as well as the
environment. Some of the known causes include long-term
exposure to environmental and occupational hazards such as
allergens, cigarette smoke, air pollution, asbestos, silica, coal dust,
beryllium, hard metals, and radiation treatments (22, 23). These
environmental factors along with genetic predisposition together
drive the development and progression of lung disease.
Despite the increasing burden of these lung diseases, current
treatment options are limited. In asthma, β2 agonists and inhaled
corticosteroids remain as the first-line treatments, however
5–25% of patients fail to respond to steroids (6, 24, 25).
Likewise, there is no effective therapy for COPD that stops
or reverses the progressive nature of the disease and current
disease management strategies primarily aim to treat associated
symptoms (3, 26). For IPF, international guidelines for the
management and treatment are lacking, with patients often
limited to the prescription of anti-fibrotic drugs (nintedanib
and pirfenidone) and broad spectrum antibiotics (azithromycin
and polymyxin) (27, 28). For lung cancer, the overall 5-year
survival rate was <5% for NSCLC until the last decade when
the advent of immunotherapies raised this to 20–30% (29–31).
Unfortunately, only 21% of NSCLC patients and 3.7% of small
cell lung cancer patients are eligible for immunotherapy (32).
Hence, the development of better treatment strategies is urgently
needed, which can be achieved through improved understanding
of the pathogenesis of CLDs.
There is growing interest in understanding host-microbiome
interactions and manipulating the lung microbiome by targeting
specific microbes or microbial products such as toxins and
metabolites as potential novel treatments. There have been
major recent advances in the understanding of the molecular
and cellular mechanisms of CLDs, and new research is
continuously revealing that many of these processes are driven
by interactions with the respiratory microbiome (6, 33, 34).
Metagenomics is the investigation of the collective genomic
material in an environment (35). DNA libraries are prepared
from samples such as bronchoalveolar lavage fluid (BALF)
and tracheal aspirates, sequenced using Miseq (next generation
sequencing technology) and analyzed using metagenomics tools.
This approach provides a broad scale analysis of microbial
species, their distribution, metabolic properties and impact
on disease. Several factors influence bacterial persistence
in the lower respiratory tract including; oxygen gradients,
nutrient availability, temperature, pH and surfactants such
as phosphatidylcholine-containing lipids (primarily dipalmitoyl
phosphatidylcholine) and sphingomyelins (36). Furthermore,
metagenomics can be used for molecular diagnostics and
surveillance of pathogens in diseases (37).
One of the key characteristics used to assess the microbiome
is diversity: the number of different species (richness) and
the abundance of different species (evenness). Diversity of
bacterial species can be measured within samples, which is
known as α-diversity (using Simpson or Shannon index) or
between samples, which is known as β-diversity (using principal
coordinate analysis) (38). Bacterial taxa found in healthy
individuals include Bacteroidetes and Firmicutes comprising of
Veillonella, Lachnospira, and Rothia that have been detected in
nasopharyngeal swabs, oral washes or bronchoalveolar lavage
(39). A microbial imbalance, known as dysbiosis, has been
associated with the development of several diseases including
lung diseases (40).
Recent studies have highlighted the modulatory role of
the microbiome in inflammation and inflammatory diseases.
The term “microbiome” refers to the aggregate of all the
commensal microbiota present on or in a particular host,
including viruses, fungi, bacteria, archaea, and protozoa (1). The
human microbiome is highly diverse, with distinct microbial
profiles at different anatomical sites, and has been implicated
in disease. For instance, it has been well established that
that microbiome in the gut plays a distinct role in the
pathogenesis of diseases such as irritable bowel syndrome,
ulcerative colitis, allergy (e.g., atopic dermatitis) and obesity
(41–45). Accordingly, recent research suggests that the resident
lung microbiome is altered during the development of lung
diseases, which allows for the colonization of pathogenic bacteria.
Several bacterial species such as Legionella (46), Escherichia
coli, H. influenzae, S. pneumoniae, Enterobacter spp. (47),
and Moraxella spp. (48) can initiate lung inflammation. Until
recently, the lungs of healthy individuals were considered to be
sterile as culture-dependent techniques were unable to detect
the presence of bacteria. However, with the development of
culture-independent techniques, microbes of different phyla and
genera have been found in the lungs and are associated with
lung disease (49). The alteration in respiratory microbiomes
during CLDs and how they are affected by challenges such
as indoor/outdoor air pollution, biomass/cigarette smoke,
and pathogenic infections are being recently elucidated. The
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immunological crosstalk between gut and lung, termed as “gut-
lung axis” can impact the health of the lung as microbiome
in lung are altered in CLDs. This involve activation of
numerous factor such as inflammasomes and microRNAs (4).
It is now well-established that the primary microbiome phyla
residing in healthy lungs include Firmicutes, Bacteroidetes,
Proteobacteria, Actinobacteria and others (49). Pathogenic
microbes, such as Pseudomonas aeruginosa and Haemophilus
influenzae, have the capacity to trigger different immune
responses. Thus, it may be beneficial to examine the role
of an altered lung microbiome in the pathogenesis and
progression of lung diseases (1). Accordingly, in this review,
we will discuss recent updates regarding the role of the
lung microbiome in the context of COPD, asthma, IPF and
lung cancer.
LUNG MICROBIOME AND ASTHMA
Asthma affects >330 million people worldwide and is a major
healthcare issue. The annual increase in asthma incidence
was 1.4% for children and 2.1% for adults between 2011
and 2015 (24, 50). It is a complex and heterogeneous
inflammatory disease with variable phenotypes. Classically,
asthma is characterized by increased type 2 immune responses
and eosinophilic inflammation (51). However, recent studies
have linked elevated type 1/17 immune responses with non-
eosinophilic (i.e., neutrophilic) inflammation especially in adults
with moderate to severe asthma (24, 51, 52). Interestingly,
exogenous factors including respiratory viral and bacterial
infections, a high-fat diet and/or obesity, air pollution and
cigarette smoke exposure are associated with severe asthma in
adults as well as with exacerbations of the disease (24, 53–56).
Unfortunately, 5–10% of asthmatics do not respond to steroid
therapies and are more likely to have severe disease. Severe
steroid-resistant (SSR) asthma is a condition where asthmatic
patients do not respond to mainstay corticosteroid therapies
(57). SSR is associated with non-eosinophilic endotypes of the
disease, including neutrophilic asthma, and involves activation
of innate immune responses, particularly those mediated by
Toll-like receptor (TLR)2 and TLR4 responses, and NLRP3
(nucleotide-binding oligomerisation domain-like receptor
family, pyrin domain-containing 3) inflammasome/interleukin
(IL)-1β responses (11, 25, 56, 58–60). The lung microbiome has
been linked SSR asthma. Recently, Durack et al., showed that
variations in bronchial microbiome composition is associated
with the immunological, steroid-responsiveness and clinical
features of asthma. Patients with asthma had an enrichment of
Haemophilus, Neisseria, Fusobacterium, Porphyromonas and
Sphingomonodaceae, and a depletion of Mogibacteriaceae and
Lactobacillales. The study also showed distinct changes in specific
microbial members after fluticasone treatment, demonstrating
that steroid treatment can alter the microbiome which may
influence steroid-responsiveness (61). Accordingly, researchers
have shown that pathogenic microbes such as Haemophilus
spp. and Chlamydia infections induce the development of SSR
experimental asthma when combined with mild to moderate
asthma models (62–67). Therefore, a thorough understanding
of the lung microbiome may be essential to understand the
immunological differences between asthma endotypes and how
to treat them.
Several studies have characterized the bacterial profile of
the lung microbiome in asthma. In asthma there is an
elevated abundance of Haemophilus influenzae, Streptococcus
pneumoniae, Staphylococcus aureus, and Moraxella catarrhalis
in nasopharyngeal swabs, compared to healthy controls. While
frequently detected as part of a normal microbiome, these
bacteria are known pathogens that can cause infectious
exacerbations (35). Furthermore, across two studies, Huang et al.,
showed thatActinobacteria can have a high abundance in patients
with severe asthma, which correlate with disease outcomes,
including elevated sputum leukocytes and eosinophils in
bronchial biopsies (68), and the abundance of Comamonadaceae,
Sphingomonadaceae, and Oxalobacteraceae in asthma patients
correlates with airway hyperreactivity (69). Denner et al., showed
that bacterial α-diversity in endobronchial brushings of asthmatic
subjects corresponds with eosinophil numbers in lavage as well
as forced expiratory volume in 1 s (FEV1) (70). The alterations
in lower airway microbiomes of patients with asthma also
correlated with FEV1 as a biomarker of airflow obstruction.
Patient with asthma with FEV1 < 60% had low α-diversity but
high β-diversity, low abundance of Firmicutes, Bacteroidetes, and
Actinobacteria and potential pathogenic genus Streptococcus and
the commensal genera Veillonella and Prevotella, compared to
asthma patients with an FEV1 > 80% (70). Overall, these studies
demonstrate that the lung microbiome has an impact on patient
outcomes in asthma.
In addition to patient outcomes, the lung microbiome is
associated with systemic and bronchial markers of inflammation
(71). In the lower airway microbiome of patient with severe
asthma, pathogenic microbesMoraxella catarrhalis,Haemophilus
spp., and Streptococcus spp. are predominate and their presence
correlates with cytokine levels (IL-8), eosinophilia, and
neutrophilia (72, 73). S. pneumoniae is another pathogenic
microbe that is associated with asthma, but conflicting reports
are available regarding its influence. In a mouse model of allergic
airway disease, it was reported that mice infected with non-lethal
S. pneumoniae as neonates before sensitization and challenge
with ovalbumin (OVA) had increased interleukin-17A (IL-17A)
production, elevated neutrophil recruitment and Th17 cells (74).
However, we previously showed that exposure to non-pathogenic
S. pneumoniae, through either infection, killed bacteria or its
components, can protect against allergic airway disease in adult
mice through the modulation of dendritic cells, natural killer
cells, and the induction of regulatory T cells (Tregs) (75–79). It
would be interesting to continue this work and examine the role
of microbial dysbiosis on the development of SSR asthma.
Microbial metabolites, such as short chain fatty acids (SCFAs)
acetate, propionate and butyrate, regulate the physiology and
immune response in humans (80). SCFAs are produced by
the gut microbiome via fermentation of dietary fibers and
are distributed across the body through the bloodstream.
SCFAs are utilized by the body to provide energy or as
signaling molecules (81, 82). SCFAs inhibit histone deacetylases
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(HDACs) and promote anti-inflammatory cell phenotypes (i.e.,
neutrophils) that maintain homeostasis, and suppress nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB)
and tumor necrosis factor-α (TNF-α) production (80, 83, 84).
Cait et al., identified SCFAs and the depletion of SCFA-producing
bacteria as a mechanistic link between the microbiome and
asthma susceptibility or severity. Exacerbation of OVA-induced
allergic lung inflammation by vancomycin treatment was due
to the lack of gut microbiome populations responsible for
producing SCFAs, particularly butyrate. This work highlighted
the potential of probiotics as a novel therapy for asthma (85).
Hougee et al., utilizing OVA induced mouse model of asthma
reported that oral administration of bacteria Bifidobacterium
breve M-16V and Lactobacillus plantarum NumRes8 reduced
the eosinophilic inflammation, OVA-specific IgE levels, and
cytokines production (86). Likewise, the protective effects of
administration of Lactobacillus rhamnosus GG and Lactobacillus
paracasei L9 have been reported against the birch pollen-induced
allergic asthma and urban airborne particular matter 2.5 µm-
induced enhancement of airway hyperresponsiveness in the
mouse model of asthma (87, 88). Huang et al., evaluated the
effect of Lactobacillus aracasei, Lactobacillus fermentum or their
combination on immune biomarkers, clinical severity and quality
of life in 160 children aged 6–18 years of age with asthma
in a double-blind, prospective, randomized, placebo-controlled
trial. Serum IFN-γ, IL-4, IgE and TNF-α levels were evaluated
for immune biomarkers, but only levels of IgE decreased
significantly in the combination treatment group. Combined L.
aracasei and L. fermentum also significantly improved quality
of life. All intervention groups had lower levels of Clostridium
compared to controls (89). This suggests that colonization by
other microorganisms, and increasing gut microbial diversity,
are potentially other protective factors against asthma (90).
However, further studies are required to better understand the
role of the microbiome in asthma and to define the potential for
therapeutic manipulation.
LUNG MICROBIOME AND COPD
The prevalence of COPD is increasing, and its management is
a formidable challenge to healthcare systems. There is growing
evidence that the lung microbiome is altered during the course
of the disease and contributes to COPD pathogenesis (91–
93). Hilty et al., provided early evidence of the presence of
dysbiosis in COPD. 16S rRNA analysis was performed on
DNA collected from swabs from the nose and oropharynx, and
bronchial brushings from the left upper lung lobe of COPD
patients and healthy controls. Sequencing showed that COPD
patients have a distinct microbiome in their lungs compared
to healthy individuals. Specifically, pathogenic Proteobacteria
(Haemophilus spp.) were more common in COPD than
Bacteroidetes, with Prevotella spp. being especially reduced (94).
Subsequent studies showed the predominance of Firmicutes,
Bacteriodetes, Proteobacteria, Fusobacteria, and Actinobacteria
in healthy individuals, in contrast to pathogenic Haemophilus,
Streptococcus, Klebsiella, Pseudomonas, and Moraxella in COPD
patients (91–93, 95, 96). We propose that the lung microbiome
is dynamic and transient, with specific taxa being present at
different stages of disease progression and impacted by clinical
factors such as age, smoking, medications, or seasonal changes
(33, 34).
Cigarette smoking is a major risk factor for many lung
diseases. Hence, researchers have investigated the effects on the
lung microbiome. A growing number of reports indicate that
smoking alters the oral and respiratory bacterial microbiome
(97–99). Limited studies have been carried out in the context
of COPD. Erb-Downward et al., assessed BALF samples from
smokers with COPD, healthy smokers and non-smokers and
showed notable β-diversity (i.e., differences in bacterial evenness)
between the cohorts which is likely caused by outgrowth of
bacteria within the population, rather than colonization of
different bacteria (91). However, contradictory results were
found in a subsequent study by Sze et al., utilizing lung
tissue samples from non-smokers, smokers without COPD, and
COPD patients where there was low diversity between non-
smokers and healthy smokers, and a high β-diversity compared
to COPD (smokers & non-smokers) (100). The disparity in
outcomes may be due to differences in samples used (BALF vs.
lung tissue) and small sample size. Nevertheless, these studies
suggest that cigarette smoke is associated with alterations in lung
bacterial microbiomes in healthy smokers and COPD patients.
Whether these changes in bacterial populations are associated
with the development and progression of COPD still needs to
be determined.
In addition to the impact of cigarette smoke on bacterial
populations, a recent study reported that cigarette smoke alters
the lung virome. In BALF samples from smokers and non-
smokers, bacterial communities were found to be similar among
the two groups; however, significant differences were found
in the lung virome, which correlated with levels of IL-8 and
arachidonic acid. Both IL-8 and arachidonic acid are involved
in COPD pathogenesis. The former is a potent neutrophil
attractant and the pro-inflammatory effects of the latter have
been reported in COPD (101, 102). In smokers, bacteriophages
infecting Prevotella, Actinomyces, Aeromonas, Capnocytophaga,
Haemophilus, Rodoferax, and Xanthomonaswere increased, while
Enhydrobacter and Morganella bacteriophages were dominated
in non-smokers (103). Future studies are required to address:
(1) which microbiome populations (bacterial, viral, fungal) in
the lung are influenced by smoking, and; (2) how changes in
the microbiome contribute to the susceptibility and progression
of COPD.
Furthermore, smoking can indirectly effect the lung
microbiome by altering the extra-cellular matrix (ECM)
(104–107). H. influenzae, S. pneumoniae, Pseudomonas, and
Moraxella are frequent pathogenic colonizers in COPD
patients (108). During non-typeable H. influenzae (NTHi)
infections, the ECM proteins fibronectin, laminin, collagen
IV, and vitronectin play critical roles in colonization. Briefly,
NTHi binds to the host vitronectin via bacterial protein
E resulting in subsequent intracellular invasion. Further,
high affinity of Hap (one of the bacterial adhesins) has
been reported for fibronectin, laminin, and collagen IV,
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which eventually aid NTHi invasion (109, 110). Likewise,
during lung infections by Streptococcus, Pseudomonas, and
Moraxella, laminin, collagen I, V, and VI are involved
in adhesion and invasion (111). Since the levels of ECM
proteins (fibronectin/fibrinogen/collagen/laminins/fibulin-
1c) are altered in patients with COPD, relationship between
smoking, pathogenic microbes and ECM need to be explored
(107, 112–114).
Research investigating the mechanism by which the lung
microbiome can influence the COPD-linked immune response
is in its infancy. Studies have shown pathogenic microbes
cause lung inflammation in healthy individuals (115–118).
The immune-stimulatory capacity of Gram-negative pathogenic
bacteria associated with COPD (Haemophilus spp. & Moraxella)
is significantly higher than Gram-negative commensal bacteria
(Prevotella spp.) (119). Further, poor oral health is an important
risk factor for inflammatory lung diseases (120). Studies
have shown that microaspiration of oral taxa (particularly
Veillonella and Prevotellla) is associated with elevated Th17
lymphocytes in lungs (115, 121). Thus, dysbiosis in the COPD
lung may be associated with COPD exacerbations (122).
Epithelial cells and alveolar macrophages form the first line
of defense against pathogens. They express pattern recognition
receptors that recognize pathogen-associated molecular patterns
to initiate the innate immune response. H. influenzae interacts
with TLR2 and activates NF-κB (the master regulator of
pro-inflammatory response) via translocation dependent and
independent pathways. In the translocation dependent pathway,
activation of NF-κB inducing kinase (NIK)–IKKα/β complex
leads to KiBα phosphorylation and there is degradation.
The NF-κB translocation-independent pathway occurs through
activation of MKK3/6–p38 mitogen-activated protein (MAP)
kinase pathway (123, 124). In addition to TLR2, TLR4 induced
NF- κB activation has also been reported in context of H.
influenzae (125, 126). Like H. influenzae, P. aeruginosa is
recognized by pattern recognition receptors. P. aeruginosa
activates NF-κB via TLRs through both TIRAP-dependent
and independent pathways. Additionally, this bacterium is
involved in the activation of MAPK cascades (127). Thus,
pathogenic microbes induce inflammatory responses that
are part of the natural defense against foreign pathogens.
However, in COPD patients, excessive, persistent and chronic
inflammation is a major driver of disease pathogenesis.
The activation of TLRs by the presence of pathogenic
microbes can further aggravate the inflammatory state in
the lungs of COPD patients (128). This eventually results
in tissue damage and the production of damage-associated
molecular patterns that further activate inflammatory pathways,
leading to a vicious cycle of pathogenesis (129). Our recent
study utilizing TLR2- and TLR4-deficient mice showed that
TLR2 and TLR4 play opposing roles in COPD pathogenesis.
TLR2 inhibition increased COPD features in an experimental
mouse model, while these features were reduced in the
absence of TLR4 (128). Thus, modulation of TLRs appear
to be a potential strategy to suppress COPD and bacteria-
induced exacerbations. However, future studies examining the
relationship between TLRs expression, bacterial load, and lung
inflammation area required. Further, the protective role of TLR-2
and 4 through activation of innate immune system should not
be ignored.
Additionally, studies have been carried out for the analysis
of microbiome dynamics associated with COPD exacerbations.
Wang et al., and Mayheve et al., utilizing sputum samples
from the COPD subjects reported that Moraxella abundance
is increased during COPD exacerbation compared to stable
COPD subjects. However, Haemophilus abundance did not
show significant change between stable and exacerbated COPD
individuals. Both Haemophilus and Moraxella are known to
form biofilms that protect them from antibiotics and immune
cells, thus their persistence is associated with repeated bacterial
exacerbations (122, 130). It is important to mention here
that different sampling procedures like BALF, sputum, lung
tissue explants represent microbiome from different respiratory
regions. Hence, future studies utilizing BALF and lung tissue
samples should be carried out to study microbiome dynamics
with different stages of COPD. Further, thresholds should be
determined to identify significant bacterial over-representations
for all sample types.
Thus, a limited number of studies have explored the role of
lung dysbiosis in COPD but it is difficult to draw any conclusions.
Although they are valuable for our understanding, there are
issues with existing studies such as the use of different samples
(BALF vs. lung tissues), limited numbers of participants, low
biomass and potential for contamination. Further studies are
required to elucidate the role of the lung microbiome in the
pathogenesis and progression of COPD. Additionally, studies
evaluating the impact of TLR-agonists should be performed.
LUNG MICROBIOME AND LUNG CANCER
The main causative factors in lung cancer are exposure
to carcinogens, cigarette smoke, toxic compounds in the
environment/industry, chronic airway inflammation driven by
pathogenic infections, and fibrosis/scarring from co-morbid lung
disease (30, 131). The lung microbiome may be altered by these
causative factors and has been linked to lung cancer progression,
phenotype and severity.
Research has shown that specific species/genera/phyla
of bacteria are associated with lung cancer progression;
specifically, Helicobacter pylori (132), Acidovorax temporans
(133), Cyanobacteria (134), Actinobacteria, Bacteroidetes,
Proteobacteria, Firmicutes (135), Cytomegalovirus (136),
Thermus, Legionella, Megasphaera, Veillonella (137),
Capnocytophaga, Neisseria and Selenomonas (138). The specific
pathogenic mechanisms of microbiome-mediated lung cancer
progression are not widely known include the effects of bacterial
toxins such as lipopolysaccharide (LPS) and inflammatory
cytokine release by immune cells. The LPS of H. pylori can
stimulate the production of pro-inflammatory factors including
TNF-α, IL-1, and IL-6. These inflammatory mediators promote
chronic lung diseases such as COPD and bronchitis that are
followed by lung cancer (133). Various other bacterial toxins also
have crucial roles in tumor initiation and progression. Cytolethal
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distending toxin (CDT), Bacteroides fragilis toxin and cytotoxic
necrotizing factor-1 can damage DNA repair machinery leading
to tumorigenesis (133, 139). The toxin microcystin from
Cyanobacteria was associated with diminished CD36 and
upregulation of poly ADP ribose polymerase 1 (PARP1) levels in
silico, which was confirmed in human lung epithelial carcinoma
cells (A427) in vitro and in human adenocarcinoma samples
(134). Similarly, heat-inactivated E. coli stimulated TLR4 and
induced NSCLC metastasis and adhesion in vivo. These effects
were specifically induced through extracellular signal-regulated
kinase (ERK)1/2 and p38 mitogen-activated protein kinases
(MAPK) pathways (140).
Some bacterial species directly promote the development of
lung cancer while some are found in lung cancer patients after
tumor has progressed. A pooled meta-analysis study suggests
that H. pylori promotes lung cancer progression by 3.24-fold
compared to controls (without known history of H. pylori
infection and lung cancer) (141). Another meta-analysis suggests
that previous lung disease with pneumonia and Mycobacterium
tuberculosis could significantly increase lung cancer risk (142).
Similarly, chronic infections with Chlamydia pneumoniae are
also associated with increased risk in male patients aged ≤55
years (143). D’Journo et al., investigated the association of the
lungmicrobiome and cancer through RT-PCR of 16S rRNA genes
of bacteria in lung cancer patients. Microbiological examination
was carried out in lung sections of patients selected for major
lung surgery. This study showed that Cytomegalovirus were
abundant in the non-cancer distal airway and parenchyma of
lung sections (144). Similarly, Lee et al., investigated the lung
microbiome in the BALF samples from lung cancer patients as
well as those with benignmass-like lesions. 16S rRNA sequencing
of BALF samples showed that two phyla (TM7 and Firmicutes)
were more abundant in lung cancer. Also, the genera Veillonella
and Megasphaera were comparatively higher in lung cancer
patients, suggesting that dysbiosis may be a biomarker for lung
cancer (137).
The association of the commensal microbiome with
development of lung cancer was further elaborated in a nested
case control study of 4,336 subjects with lung cancer and
10,000 controls. This study was performed with subjects 40–84
years of age to find links between the use of antibiotics and
cancer risk. The relative risk of lung cancer was 2.52 (95%
CI, 2.25–2.83) in subjects receiving ≥10 antibiotics compared
to controls with no antibiotics. The higher relative risk was
probably because of inflammatory conditions due to frequent
infection and alterations in lung microbiomes in patients taking
antibiotics (145).
The lung microbiome is critical in maintaining immune
homeostasis in the airway mucosa. Alterations in the normal
lung microenvironment can have deleterious effects including
tumor progression. An in vivo mouse model study showed that
antibiotic treatment makes mice more prone to the formation
of engrafted Lewis lung carcinoma and B16/F10 melanoma,
resulting in increased tumor multiplicity and sizeable tumor foci
in the lungs and reduced mean survival. Treatment resulted
in the malfunction of γδT17 cell responses in the lungs,
leading to more invasive tumor progression. Restoration of
altered immune surveillance in antibiotic treated mice could
be achieved by adding IL-17 producing γδT cells and by
supplementation with IL-17. The promotion of lung cancer
development by commensal bacteria is mediated by activating
lung-resident γδT cells to provoke inflammation (146). This
recent discovery in mice introduced a new cancer-promoting
mechanism for microbiome-activated γδT17 cells in lung cancer,
highlighting the complex balance between inflammation and
immune surveillance in the lung. Collectively, these studies
highlight the significance of commensal bacteria in strengthening
the immune response and protecting against lung cancer (147).
In addition to lung cancer progression, the lung microbiome
can be linked to cancer phenotype. More specifically, the
distribution of bacterial species can vary between different
lung cancer subtypes. Comamonas, Rhodoferax, Acidovorax,
Polarmonas, and Klebsiella are often observed in squamous cell
carcinoma (SCC) but not adenocarcinoma (133). Apopa et al.,
investigated the microbiome composition in lung squamous
cell carcinoma, adenocarcinoma and healthy control tissues
and found that the phylum Cyanobacteria was persistent
in adenocarcinoma samples (134). The potential association
between salivary microbiome and lung cancer occurrence
was evaluated in subjects with lung adenocarcinoma and
squamous cell carcinoma. Deep sequencing analysis of the
salivary microbiome of these lung cancers were compared with
healthy controls, which showed that the genera Veillonella,
Capnocytophaga, Neisseria, and Selenomonas were remarkably
higher in subjects with cancer compared to controls (138). A
recent clinical study of 143 lung cancer patients and 33 healthy
controls revealed the presence of a distinct lung microbiome
in the cancer group compared to controls. Particularly, in
patients with squamous cell carcinoma, Acidovorax temporans
was detected in tumor tissues by fluorescent in situ hybridization.
This was further confirmed with 16S rRNA analysis where
Acidovorax dominated in squamous cell carcinoma with
mutations in the TP53 gene, but was not observed in
adenocarcinoma (133).
The characterization of lung microbiomes in lung cancer
patients show heterogeneity among various stages of disease.
Analysis of seven and 151 patients with stage IV and I-
IIIA stage lung cancer, respectively, showed that the genus
Thermos was more abundant in stage IV (46). Huang
et al., analyzed the differential taxonomy of squamous cell
carcinoma with (SCC_M1) or without metastasis (SCC_M0)
and lung adenocarcinoma with (AD_M1) or without metastasis
(AD_M1). In stage I-III, the phylum Firmicutes and genera
Veillonella, Megasphaera, Actinomyces and Arthrobacter were
increased in AD_M0 compared to SCC_M0. In stage IV,
the genera Capnocytophaga and Rothia were decreased in
AD_M1 compared with SCC_M1. Interestingly, no difference
was observed in these 6 genera among former smoking and non-
smoking groups indicating that smoking was not responsible for
the variation in the differential genera (148).
Recently, researchers have began focusing on opportunities
to treat lung cancer by manipulating the lung microbiome.
Targeting the microbiome and their products (toxin/metabolites)
could be a promising approach as adjunct therapies or alone
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as suggested by various in vivo and in vitro studies (149).
Oral administration of Enterococcus hirae and Barnesiella
intestinihominis enhanced the therapeutic efficacy of
cyclophosphamide and increased the survival in lung cancer
patients. Bacteria specific memory Th1 cell immune responses
selectively predicted the longer progression free survival in
patients with advanced lung cancer (150). Another in vivo
study in mice evaluated the efficacy of an antitumor vaccine
prepared from B. subtilis B-7025 in experimental models of
solid sarcoma 37 (S37) and metastatic Lewis lung carcinoma.
The vaccine was prepared on the basis of lectines from B.
subtilis B-7025 and its synergetic effects tested with concurrent
administration of a probiotic mixture of Enterococcus faecium K-
50 and Saccharomyces cerevisiae 14K, compared to vaccine alone.
Combination therapy resulted in potent synergistic anti-tumor
effects in S37-bearing mice. Moreover, there was 2 to 2.5-fold
inhibition of metastasis of Lewis lung carcinoma compared to
vaccine alone (151). Similarly, an in vitro study in a lung cancer
cell line (SK-MES-1) showed probiotics Lactococcus lactis KC24
and NK34 from Korean fermented food Kimchi resulted in
86.53 ± 0.96% and 96.71 ± 0.00% reduction in lung cancer
cell viability, respectively (152, 153). Taken together, these data
show that targeting the microbiome or its metabolites could be a
novel way to manage lung cancer progression. However, more in
vitro and in vivo studies are essential to validate and explain the
evidence-based beneficial roles of probiotics in lung cancer.
LUNG MICROBIOME AND IPF
Recently, a potential role of microbiomes in IPF has been
reported (154, 155). Specifically, it was shown that changes in
bacterial diversity were related to disease progression. However,
how the microbiome influences respiratory function and how it
can be used as a clinical marker in IPF remains to be elucidated.
Some potential roles of the microbiome in the progression of
IPF have been reported (156). Dysbiosis and the colonization
of pathogenic bacteria can cause epithelial cell injury and
activate immune responses leading to pro-inflammatory and pro-
fibrotic cascades resulting in structural changes in the lungs
(157). Current therapies for IPF are limited and glucocorticoids
or immunosuppressive agents are associated with increased
risk of death and hospitalization. Fortunately, antibiotics can
improve quality of life and reduce mortality suggesting that
the microbiome may have a role in the pathogenesis of the
disease (158–160).
Interestingly, studies have reported that BALF from IPF
patients have changes in the lung microbiome due to changes
in the abundance of the phyla Firmicutes, Proteobacteria,
Bacteroidetes, and Actinobacteria. Specifically, there was a
decrease in diversity due to an increase in Firmicutes and
a decrease in Proteobacteria (161). This loss of diversity
correlated with IPF symptoms including low forced expiratory
and vital capacity, high serum surfactant protein-D and lactate
dehydrogenase (both clinical biomarkers of IPF progression).
The decrease of lung bacterial diversity correlated with pro-
inflammatory and pro-fibrotic cytokines in the alveoli in IPF
patients, suggesting that loss of diversity may have some impact
on pathogenesis (156).
A higher bacterial burden has been observed in patients
with IPF who had minor allele at the promoter of the mucin
5B (MUC5B), a gene that encodes a mucin family of protein
which composes mucus, suggesting that the bacterial burden
and MUC5B mutation are linked mechanistically (154, 162–
165). This suggests that MUC5B may play a key role in IPF
pathogenesis. Moreover, the development and progression of
IPF has been associated with single nucleotide polymorphisms
in microbially linked genes such as Toll-interacting proteins,
which operate as an adaptor protein for TLRs that mediate
microbe-host interactions (165, 166). Some studies found that
BALF neutrophilia and expression levels of genes involved in host
defense response (NLRC4, PGLYRP1, MMP9, DEFA4) as well as
encoding antibacterial peptides (SLPI andCAMP) were increased
suggesting a correlation with both increased bacterial burden
and disease progression in IPF (167). The absence of secretory
leukocyte protease inhibitor (SLPI), a host protein implicated
in IPF, leads to the impairment of collagen gene expression
in a mouse model of bleomycin-induced lung fibrosis (168).
This suggests that there is a potential mechanistic link between
the microbiome and lung fibrosis. During IPF exacerbations,
patients have increased numbers of neutrophils in BALF due
to increased bacterial burden, suggesting that the microbiome
might play a causative role in exacerbations (169). Overall, these
studies suggest that genetics and transcriptomic alterations in
innate immune response genes are all associated with increases in
bacterial load in IPF and its progression. This increase in bacterial
burden is associated with increased epithelial cell damage, which
leads to impaired lung function (170, 171). Interestingly, study
demonstrate that fibroblasts obtained from IPF patients who
had an altered microbiome or increased microbial load showed
enhanced expression of the α-smooth muscle actin gene, which
is a marker of lung fibrosis (172). Moreover, it has been
reported that lung dysbiosis induces pro-inflammatory cytokines,
including IL-17B and TNF-α, that cooperatively activate lung
epithelial cells leading to inflammation and fibrosis (160),
suggesting that there is a strong mechanistic link between the
microbiome and fibrogenesis.
Despite these studies demonstrating the association between
the microbiome and fibrogenesis, key questions remain
unanswered. Firstly, is microbial diversity or the abundance of
specific species responsible for the development and progression
of IPF. Secondly, can the lung microbiome serve as a biomarker
for the development and progression of IPF. These questions
remain challenging and require further study.
DISCUSSION AND FUTURE
PERSPECTIVES
Numerous studies have shown important roles for the lung
microbiome in both the maintenance of respiratory homeostasis
and pathogenesis of CLDs (1, 4, 34). Thus, there is an exciting
opportunity to target the lung microbiome for the treatment of
CLDs. Even though microbiome modulation as a therapy for
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CLDs is currently limited, antibiotics, anti-inflammatory agents,
probiotics and diet can help significantly in reducing disease
exacerbations (33, 173, 174). Importantly, proper analysis and
understanding the spectrum of the effects of the lungmicrobiome
creates new avenues for the development of targeted therapies as
well as prognostic and diagnostic markers for CLDs (34).
The universal adoption of culture independent techniques
including 16s rRNA gene sequencing and now metagenomics
has advanced the study of the lung microbiome in recent years.
However, caution is needed when applying these techniques as
laboratory contamination from reagents can impact the analysis
of microbiome sequencing (175, 176). Indeed, contamination
can heavily compromise the consistency of microbiome data,
specifically in lowmicrobiome biomass samples such as the lungs.
A study investigating the extent of contamination attributed by
consumables such as the PCR master mix and DNA extraction
kits during 16S rRNA gene sequencing revealed that the master
mix was a prime source. This was supported by a significantly
reduced blank signal and improved precision by enzymatic
removal of contamination (177). Thus, there is a need to optimize
and standardize methods of DNA extraction from various sample
types when sequencing the microbiome.
It is well known that there is a close relationship between
the lung microbiome and inflammation and innate immune
responses (178–181). LPS is a classical bacterial component
that can induce inflammation in the lungs, which activates
innate immune responses in humans and mice (182). LPS acts
via TLR4 and induces proinflammatory signaling in COPD
as well as in asthma (183–185). Other bacterial components
like peptidoglycans and lipoteichoic acids in Gram-positive
bacteria, act synergistically to induce lung inflammation by
neutrophilic influx and by release of IL-6 (186–188). Likewise,
outer membrane vesicles derived from lung commensal microbes
(Bacteroides and Prevotella) can stimulate IL-17B production
through TLR-MyD88 adaptor signaling to promote IPF (160).
The main therapy for asthma includes anti-inflammatory
corticosteroids, which are generally administered in
combination with short- or long-acting β2-adrenoceptor
agonists (bronchodilators) (24, 189). Although combination
therapies improve symptoms by suppressing type 2 cytokine
responses, inflammation and by dilating the airways, they
possess nonspecific anti-inflammatory activity and have long
term adverse side effects if administered at higher doses (6). In
asthma, the increased load and alterations to the composition of
the lung microbiome is correlated with elevated eosinophil and
neutrophil numbers in the bronchi, and IL-1β, IL-6, IL-17A, IL-8,
IL-12, and TNF-α levels in sputum (190). A healthy microbiome
during the early stage of life plays a key role in lung development,
reducing the possibility of the development of asthma (191),
providing impetus for giving probiotics and prebiotics in early
life to improve the microbiome (192). Pre-clinical investigations
into the therapeutic potential of pro- and prebiotics have shown
that altering the microbiome can influence overall immunity
and reduce allergic inflammation and sensitization, suggesting
the protective effect of pre- and probiotics for asthma (193).
Furthermore, macrolide-based antibiotics have been studied as
a long-term treatment option to decrease airway inflammation
and hypersensitiveness (194). In a landmark study by Gibson
et al., azithromycin treatment led to decreased bacterial burden
in the lung and gut, which reduced asthma exacerbations (195).
In investigations of the lung microbiome with corticosteroid
treatment, Goleva et al., showed that there are specific Gram-
negative bacteria which trigger corticosteroid resistance via
factor-b–associated kinase-1 (TAK1)/MAPK activation (196).
Overall, the use of pre- and probiotic supplements, macrolide
antibiotics and corticosteroids can reduce asthma exacerbations
by decreasing harmful bacterial load (194).
Likewise, for IPF, various reports suggest that targeting the
microbiome can increase patients’ quality of life (15). In an
observational pilot study in 14 advanced IPF patients, treatment
with the combination of the anti-viral drug ganciclovir for 2
weeks (5 mg/kg twice daily) and prednisolone reduced disease
progression in eight patients as shown by improvement in
forced vital capacity (197). This study suggests that there
might be a viral co-factors contributing to IPF progression that
can be further validated through randomized controlled trials
(197). Similarly, co-trimoxazole, a combination of trimethoprim
and sulfamethoxazole bactericidal drugs, reduced respiratory
infections and mortality, suggesting the use of antibiotics may be
beneficial as a combination therapy along with standard drugs
for IPF (198). Additionally, there are two ongoing clinical trials
with antibiotic treatment in IPF patients. In one, the macrolide
azithromycin is being used to treat cough and improve lung
function1. In the second, a conjugated therapy of antibiotics
co-trimoxazole and doxycycline is being tested in IPF patients2.
In COPD, bronchoscopy sampling from the lower respiratory
tract showed that 54% of exacerbations are due to bacterial
infections, which shows the potential of anti-bacterial agents
(199). In a longitudinal clinical study, antibiotic treatments
reduced harmful bacteria, whereas corticosteroids led to
increased pathogenic bacteria levels, which clearly shows
the effectiveness of antibiotic treatment in COPD (200). A
randomized clinical trial conducted by Clancy et al., found
that an oral non-typeable H. influenzae vaccine did not protect
patients with COPD against exacerbations although patients
were not stratified for H. infleunzae carriage (201). Similarly, a
recent systematic review indicated that there was no reduction
in the severity and frequency of acute exacerbations after oral
administration of H. influenzae vaccine in people with chronic
bronchitis and COPD (202). However, more positive results may
be achieved if patients were stratified and treated according
to whether they were H. influenzae positive. Apart from the
conventional therapy with inhaled corticosteroids, long-acting
muscarinic antagonist and long-acting β-agonist, antibiotics
and anti-inflammatory treatment helps in overcoming COPD
exacerbations. However, studies are required to define their
effects on the lung microbiome (203).
Pre-clinical and clinical studies suggest that associations of
the microbiome with lung cancer and further studies explaining
the nature of these interactions are needed (204). Detection
of specific bacteria like Veillonella and Capnocytophaga by
1https://clinicaltrials.gov/ct2/show/NCT02173145
2https://clinicaltrials.gov/ct2/show/NCT02759120
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FIGURE 1 | Role of lung microbiome in the pathogenesis of chronic lung diseases: Pathogenic microbes are predominately present in the lungs of patients with
chronic respiratory diseases. This results in enhanced production of proinflammatory mediators, which eventually leads to oxidative stress induced dysregulation of
cell cycle (lung cancer) or exacerbations associated with asthma/COPD.
16S sequencing in saliva samples from lung cancer patients
confirm alterations in the microbiome in lung cancer (138).
Furthermore, immunotherapy with monoclonal antibodies with
immune checkpoint inhibitors like programmed cell death
(PD)-1 and targeting its ligand PD-L1 is used in many metastatic
cancers as a therapy (205). Interestingly, the use of antibiotics
in lung cancer patients resulted in reduced PD-1 response due
to dysbiosis which clearly shows the role of microbiome in lung
cancer (206). Until now, there are no reports of people using any
specific treatments to target the microbiome during lung cancer,
which may be a potential therapeutic and diagnostic tool.
Overall, targeting the lung microbiome and reverting
dysbiosis may prove beneficial in CLDs. The use of probiotics
and antibiotics appear beneficial (Figure 1), but robust cause and
effect is lacking, and it is essential that treatment studies and
translational research are performed to understand and apply
therapeutic interventions. These then need to be formally tested
in clinical trials and then implemented into clinical practice.
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